Spyre Therapeutics (SYRE) Cash from Financing Activities (2015 - 2026)
Spyre Therapeutics posted quarterly Cash from Financing Activities of $12.3 million for Q1 2026, up 9704.0% year-on-year from $125000.0 in Q1 2025, and down 96.08% on a QoQ basis from $312.8 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Cash from Financing Activities data on file, last reported at $12.3 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 9704.0% year-over-year to $12.3 million; the trailing twelve-month figure through Mar 2026 stood at $321.2 million (up 34.45% YoY), and the FY2025 full-year result was $309.0 million, down 24.79% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $12.3 million, down from $312.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $312.8 million in Q4 2025 and bottomed at -$12.5 million in Q3 2023.
- The 5-year median for Cash from Financing Activities is $731000.0 (2025), against an average of $66.8 million.
- Peak annual rise in Cash from Financing Activities reached 2045175.0% in 2023, while the deepest fall reached 9539.23% in 2023.
- A 5-year view of Cash from Financing Activities shows it stood at -$8000.0 in 2022, then jumped by 2045175.0% to $163.6 million in 2023, then soared by 37.89% to $225.6 million in 2024, then surged by 38.66% to $312.8 million in 2025, then slumped by 96.08% to $12.3 million in 2026.
- The last three Cash from Financing Activities figures came in at $12.3 million (Q1 2026), $312.8 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | 12.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.26 Mn |
| Mar 31, 2026 | 12.26 Mn |
| Dec 31, 2025 | 312.81 Mn |
| Dec 31, 2025 | 312.81 Mn |
| Sep 30, 2025 | -4.64 Mn |
| Sep 30, 2025 | -4.64 Mn |
| Jun 30, 2025 | 731,000.00 |
| Jun 30, 2025 | 731,000.00 |
| Mar 31, 2025 | 125,000.00 |
| Mar 31, 2025 | 125,000.00 |
| Dec 31, 2024 | 225.60 Mn |
| Dec 31, 2024 | 225.60 Mn |
| Sep 30, 2024 | 12.78 Mn |
| Sep 30, 2024 | 12.78 Mn |
| Jun 30, 2024 | 360,000.00 |
| Jun 30, 2024 | 360,000.00 |
| Mar 31, 2024 | 172.17 Mn |
| Mar 31, 2024 | 172.17 Mn |
| Dec 31, 2023 | 163.61 Mn |
| Dec 31, 2023 | 163.61 Mn |
| Sep 30, 2023 | -12.53 Mn |
| Sep 30, 2023 | -12.53 Mn |
| Jun 30, 2023 | 209.99 Mn |
| Jun 30, 2023 | 209.99 Mn |
| Mar 31, 2023 | 10,000.00 |
| Mar 31, 2023 | 10,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | -130,000.00 |
| Sep 30, 2022 | -130,000.00 |
| Jun 30, 2022 | 42.80 Mn |
| Jun 30, 2022 | 42.80 Mn |
| Mar 31, 2022 | 12,000.00 |
| Mar 31, 2022 | 12,000.00 |
| Dec 31, 2021 | 80,000.00 |
| Dec 31, 2021 | 80,000.00 |
| Sep 30, 2021 | 1.14 Mn |
| Sep 30, 2021 | 1.14 Mn |
| Jun 30, 2021 | -192,000.00 |
| Jun 30, 2021 | -192,000.00 |
| Mar 31, 2021 | 362,000.00 |
| Mar 31, 2021 | 362,000.00 |
| Dec 31, 2020 | 24.68 Mn |
| Dec 31, 2020 | 24.68 Mn |
| Sep 30, 2020 | 258,000.00 |
| Sep 30, 2020 | 258,000.00 |
| Jun 30, 2020 | 129.29 Mn |
| Jun 30, 2020 | 129.29 Mn |
| Mar 31, 2020 | 282,000.00 |
| Mar 31, 2020 | 282,000.00 |
| Dec 31, 2019 | 676,000.00 |
| Dec 31, 2019 | 676,000.00 |
| Sep 30, 2019 | 311,000.00 |
| Sep 30, 2019 | 311,000.00 |
| Jun 30, 2019 | -319,000.00 |
| Jun 30, 2019 | -319,000.00 |
| Mar 31, 2019 | 65.06 Mn |
| Mar 31, 2019 | 65.06 Mn |
| Dec 31, 2018 | 17.26 Mn |
| Dec 31, 2018 | 17.26 Mn |
| Sep 30, 2018 | 1.06 Mn |
| Sep 30, 2018 | 1.06 Mn |
| Jun 30, 2018 | 38.06 Mn |
| Jun 30, 2018 | 38.06 Mn |
| Mar 31, 2018 | 688,000.00 |
| Mar 31, 2018 | 688,000.00 |
| Dec 31, 2017 | 684,000.00 |
| Dec 31, 2017 | 684,000.00 |
| Sep 30, 2017 | -118,000.00 |
| Sep 30, 2017 | -118,000.00 |
| Jun 30, 2017 | 11.55 Mn |
| Jun 30, 2017 | 11.55 Mn |
| Mar 31, 2017 | 96,000.00 |
| Mar 31, 2017 | 96,000.00 |
| Sep 30, 2016 | 76,000.00 |
| Sep 30, 2016 | 76,000.00 |
| Jun 30, 2016 | 49.39 Mn |
| Jun 30, 2016 | 49.39 Mn |
| Mar 31, 2016 | -98,000.00 |
| Mar 31, 2016 | -98,000.00 |
| Dec 31, 2015 | -203,000.00 |
| Dec 31, 2015 | -203,000.00 |
| Sep 30, 2015 | -970,000.00 |
| Sep 30, 2015 | -970,000.00 |
| Jun 30, 2015 | -831,000.00 |
| Jun 30, 2015 | -831,000.00 |
| Mar 31, 2015 | 43.68 Mn |
| Mar 31, 2015 | 43.68 Mn |